economybharat.com

We Can Cover You
Click here
Facebook Youtube Instagram Linkedin
13
13

vaccine

PopVax is Awarded 2 Million USD as One of the Winners of the BARDA Patch Forward Prize for its Seasonal Influenza Vaccine built on a Novel mRNA-encoded Immunogen Display Architecture Delivered via Dissolvable Microarray Patch OG_Companylog_93109.jpg

PopVax is Awarded 2 Million USD as One of the Winners of the BARDA Patch Forward Prize for its Seasonal Influenza Vaccine built on a Novel mRNA-encoded Immunogen Display Architecture Delivered via Dissolvable Microarray Patch

creativebharatgroup@gmail.com January 14, 2025
PopVax, an Indian full-stack biotechnology company developing broadly-protective mRNA vaccines using machine learning-enabled computational protein design, is...
Read More Read more about PopVax is Awarded 2 Million USD as One of the Winners of the BARDA Patch Forward Prize for its Seasonal Influenza Vaccine built on a Novel mRNA-encoded Immunogen Display Architecture Delivered via Dissolvable Microarray Patch
ExpreS2ion announces approval to initiate a Phase I clinical trial of ES2B-C001, its novel therapeutic vaccine, being developed for HER2-expressing breast cancer

ExpreS2ion announces approval to initiate a Phase I clinical trial of ES2B-C001, its novel therapeutic vaccine, being developed for HER2-expressing breast cancer

creativebharatgroup@gmail.com December 2, 2024
Hørsholm, Denmark, 2 December 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies...
Read More Read more about ExpreS2ion announces approval to initiate a Phase I clinical trial of ES2B-C001, its novel therapeutic vaccine, being developed for HER2-expressing breast cancer
PopVax Announces that the U.S. National Institute of Allergy and Infectious Diseases will Conduct and Sponsor the U.S.-based Phase I Clinical Trial of PopVax’s Next-Generation mRNA-LNP COVID-19 Vaccine as part of the U.S. Government’s Project NextGen OG_Companylog_92449.jpg

PopVax Announces that the U.S. National Institute of Allergy and Infectious Diseases will Conduct and Sponsor the U.S.-based Phase I Clinical Trial of PopVax’s Next-Generation mRNA-LNP COVID-19 Vaccine as part of the U.S. Government’s Project NextGen

creativebharatgroup@gmail.com November 14, 2024
MUMBAI, India & HYDERABAD, India:  PopVax, an Indian full-stack biotechnology company developing novel...
Read More Read more about PopVax Announces that the U.S. National Institute of Allergy and Infectious Diseases will Conduct and Sponsor the U.S.-based Phase I Clinical Trial of PopVax’s Next-Generation mRNA-LNP COVID-19 Vaccine as part of the U.S. Government’s Project NextGen
ExpreS2ion and Evaxion announce positive preclinical data for cytomegalovirus (CMV) vaccine program ES2B-I002 b909c1992282df79_400x400ar.jpg

ExpreS2ion and Evaxion announce positive preclinical data for cytomegalovirus (CMV) vaccine program ES2B-I002

creativebharatgroup@gmail.com November 12, 2024
Hørsholm, Denmark, 12 November 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion...
Read More Read more about ExpreS2ion and Evaxion announce positive preclinical data for cytomegalovirus (CMV) vaccine program ES2B-I002
Medidata Launches Bundled Solutions to Support Oncology and Vaccine Trials, Accelerating Study Design and Execution OG_NewsReleaseCompanyLogo_92281.jpg

Medidata Launches Bundled Solutions to Support Oncology and Vaccine Trials, Accelerating Study Design and Execution

creativebharatgroup@gmail.com November 2, 2024
New York, United States:   Medidata, a Dassault Systèmes brand and leading provider...
Read More Read more about Medidata Launches Bundled Solutions to Support Oncology and Vaccine Trials, Accelerating Study Design and Execution